Want to join the conversation?
Marc Goodman of UBS asks about the breakdown of Opdivo sales and what indications it's coming from. $BMY said that on Opdivo, it's very difficult to give exact numbers by indications. These are relatively small data sets and dynamic. Trends are clear, but the company is not braking down sales by indication by quarter.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.